Effect of cholecystectomy on liver fat and fibrosis in metabolic dysfunction-associated steatotic liver disease patients

Figure 1 Patent recruitment and follow-up flowchart. NAFLD: Non-alcoholic fatty liver disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; Chx: Cholecystectomy; MRI: Magnetic resonance imaging; ECG: Electrocardiography; HOMA-IR: Homeostasis model assessment index.

Figure 2 Evolution of biological scores of hepatic steatosis. LAP: Lipid accumulation product; FLI: Fatty liver index; HSI: Hepatic steatosis index.

Figure 3 Evolution of liver fibrosis according to the exposure factor. ARFI: Acoustic radiation force fibrosis.

Figure 4 Evolution of biological scores of fibrosis according to the exposure factor. FIB4: Fibrosis 4; BARD: Body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes mellitus; APRI: Aspartate aminotransferase/platelet ratio index.

Figure 5 Evolution of the homeostasis model assessment index according to the exposure factor. HOMA-IR: Homeostasis model assessment index.

Figure 6 Evolution of amino-transferases according to the exposure factor. ALT: Alanine aminotransferase.